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Lipinski’s ruleAbstract In an attempt to ﬁnd a new class of antimicrobial agents, a series of thienopyrimidin-
4(3H)-thiones 4(H1–H36) were synthesized and evaluated for in vitro antifungal activity against
Candida albicans (NCIM 3471), Aspergillus niger (NCIM 545), and Penicillium chrysogenum
(NCIM 709). The title compounds were synthesized by thionation of thienopyrimidin-4(3H)-ones
3(H1–H36) using Lawesson’s reagent. All the compounds were characterized using elemental ana-
lytical (C, H, and N) and spectral (FT-IR, 1H NMR, 13C NMR and MS) data. Among the tested
compounds, 5-(4-chlorophenyl)-2-(pyridin-3-yl)thieno[2,3-d]pyrimidine-4(3H)-thione 4(H11), 2-sul-
fanyl-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine-4(3H)-thione 4(H18), and 2-(butylsulfa-
nyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine-4(3H)-thione 4(H32) were identiﬁed as
potentially excellent antifungal agents. They exhibited potent antifungal activity against C. albicans
(MIC; 4 lg/mL), A. niger (MIC; 2 lg/mL), and P. chrysogenum (MIC; 2 lg/mL) comparable with
that of ketoconazole. The binding mode of compounds by SP docking studies shows that it ﬁts well
into the active site cavity of DHFR. Lipinski’s rule and in silico ADME pharmacokinetic param-
eters are within the acceptable range deﬁned for human use thereby indicating their potential as
drug-like molecules.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Fungi are heterotrophic eukaryotic organisms which can grow
on almost any surface. Fungal infections have become more
frequent over the last few decades. In particular, past 2 decades
have witnessed a dramatic rise in the incidence of life-threaten-
ing systemic fungal infections. This can be attributed to an in-
crease in the number of immunocompromised patients,
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invasive instruments, such as urinary catheters, has also
increased, increasing the number of patients who are at high
risk of invasive fungal infections [1]. The efﬁcacy of current
antifungal drugs may be limited owing to increased toxicity,
lower efﬁcacy rates, and drug resistance [2]. Various classes
of antifungal drugs are in use. Lipid-based formulations of
the polyene macrolide amphotericin B (AmB) are being devel-
oped to improve efﬁcacy in invasive fungal infections, and new
azoles have been developed for use in both systemic and
superﬁcial fungal infections. A newer class of agents, the
echinocandins, is also showing considerable potential in the
treatment of many fungal infections. The new agents and
delivery systems are at various stages of development.
A large number of thienopyrimidines have been reported in
the literature to be virucides, bactericides, fungicides,
acaricides and insecticides [3,4]. Condensed thienopyrimidines
have antibacterial [5], antihistaminic [6], analgesic, anti-
inﬂammatory [7,8,9] and antimalarial properties [10]. Various
condensed quinazoline and thienopyrimidines systems have
been studied for their biological activities [11,12,13]. A large
number of tetrahydrobenzothieno derivatives have been
reported to be anticancer, antibacterial and antifungal agents
[14]. Several thienopyrimidones have also been synthesized
and evaluated for anticonvulsant activity [15].
The development of new classes of antifungal agents with
good potency against these Candida species is a high priority.
The vast majority of the current antifungal agents target the
fungal cell wall or its biosynthesis, leaving many of the essen-
tial metabolic functions unexplored as therapeutic targets. One
such essential enzyme, dihydrofolate reductase (DHFR), has
long been appreciated as an effective target for antimicrobial
therapy. As DHFR is also essential to human cells, an effective
antifungal antifolate design must take advantage of differences
in the pathogenic enzyme relative to the human enzyme. In
continuation of our research program to ﬁnd out bioactive thi-
enopyrimidines [16], we aimed to synthesize, characterize some
novel thieno[2,3-d] pyrimidin-4(3H)-thione derivatives and
evaluate them for antifungal activity.
Dihydrofolate reductase, or DHFR, is an enzyme that re-
duces dihydrofolic acid to tetrahydro folic acid, using NADPH
as an electron donor, which is required for de novo synthesis of
purines, thymidylic acid, and certain amino acids. DHFR cat-
alyzes the transfer of a hydride from NADPH to dihydrofo-
late, with an accompanying protonation, to produce
tetrahydrofolate. In the end, dihydrofolate is reduced to tetra-
hydrofolate, and NADPH is oxidized to NADP+. DHFR has
a critical role in regulating the amount of tetrahydrofolate in a
cell. Tetrahydrofolate and its derivatives are essential for syn-
thesizing purine and thymidylate, which are important for cell
proliferation and cell growth in Candida albicans.
In the present research our strategy was to synthesize differ-
ent thienopyrimidines which are isosteric with the adenine ring
of the NADPH. These are assumed to compete with NADPH
for binding at the catalytic domain of DHFR and inhibit fur-
ther conversion of dihydrofolic acid to tetrahydrofolic acid.2. Experimental
All chemicals and reagents used were of laboratory grade and
were purchased from E Merck Ltd., Loba Chemicals Ltd.,Sigma–Aldrich Ltd. and Ranbaxy Chemicals Ltd., India. Each
solvent used was dried and puriﬁed, as and when required.
Melting-points reported herein are uncorrected which were
determined in open capillaries using the Thiele melting point
apparatus. Reactions were monitored using thin-layer chroma-
tography (TLC), which was performed on coated silica gel G
plates. The plates were activated by heating (120 C) for
30 min. They were developed using benzene: Methanol (1:0.1)
solvent system and the spots were visualized by exposure to io-
dine vapors. IR spectra were recorded from KBr disks using a
Shimadzu 8400-S FTIR, and elemental analyses were carried
out using a Flash EA-1112 CHN analyzer (Thermo Finnigan,
Italy). The 1H NMR and 13C NMR spectra of the synthesized
compounds were obtained using a Bruker DRX-300
(300 MHz) NMR spectrometer. The chemical shifts obtained
are reported in d ppm. The mass spectra of the compounds were
obtained using a JMS-T100LC (Accu TOF) mass spectrometer
(DART-MS), at the CDRI, Lucknow.2.1. General procedure for the synthesis of 2,5,6-
trisubstitutedthieno[2,3-d]pyrimidine-4(3H)-thione 4
(H1–H36)
The intermediate 3 (H1–H36) compounds (0.01 mol) and xy-
lene (10 mL) were reﬂuxed for 45–60 min, Lawesson’s reagent
(0.03 mol) was added drop wise to the reﬂuxing solution for
1 h. The reaction mixture was allowed to reﬂux and stirred
for 10 h. The progress of the reaction was monitored using
TLC. After the reaction mixture was cooled, it was ﬁltered.
The ﬁltrate was evaporated under reduced pressure, yielding
the product. The crude product was recrystallized from alcohol
and dimethyl formamide. This afforded colorless crystals of
target 4 (H1–H36) compounds.
2.1.1. 5,6-Dimethyl-2-(pyridin-2-yl)thieno[2,3-d]pyrimidine-4
(3H)-thione 4(H1)
IR (KBr) cm1: 3275 (amine N–H), 3023 (Ar C–H), 1088
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.53 (1H, s, thioam-
ide), 8.72–7.46 (4H, m, arom), 2.23 (3H, s, CH3), 2.23 (3H, s,
CH3);
13C NMR (DMSO-d6) d (ppm): 183.90, 159.30, 156.57,
149.40, 148.40, 137.60, 125.87, 124.74, 124.49, 121.27, 120.63,
14.61, 13.16; M.S.: m/z- 273, 274 (M+1), 275 (M+2), 241
(M–S), 195, 163; CHN calcd. for C13H11N3S2, 273.37, C,
57.12; H, 4.06; N, 15.37. Found C, 56.98; H, 4.01; N, 15.03.
2.1.2. 5,6-Dimethyl-2-(pyridin-3-yl)thieno[2,3-d]pyrimidine-4
(3H)-thione 4(H2)
IR (KBr) cm1: 3220 (amine N–H), 3135 (Ar C–H), 1073
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.80 (1H, s, thioam-
ide), 8.92–7.49 (4H, m, arom), 2.228 (3H, s, CH3), 2.225 (3H, s,
CH3);
13C NMR (DMSO-d6) d (ppm): 183.90, 159.13, 156.57,
151.32, 148.72, 135.33, 132.71, 125.87, 124.87, 124.49, 120.63,
14.61, 13.16; M.S.: m/z- 273, 274 (M+1), 275 (M+2), 241
(M–S), 195, 163; CHN calcd. for C13H11N3S2, 273.37, C,
57.12; H, 4.06; N, 15.37. Found C, 56.95; H, 3.98; N, 15.01.
2.1.3. 5,6-Dimethyl-2-(pyridin-4-yl)thieno[2,3-d]pyrimidine-4
(3H)-thione 4(H3)
IR (KBr) cm1: 3190 (amine N–H), 3103 (Ar C–H), 1097
(C‚S);1H NMR (DMSO-d6) d (ppm): 12.58 (1H, s, thioam-
S266 S.B. Bari, N.G. Haswaniide), 8.66–7.70 (4H, m, arom), 2.23 (3H, s, CH3), 2.23 (3H, s,
CH3);
13C NMR (DMSO-d6) d (ppm): 183.90, 156.69, 156.57,
150.21, 137.74, 125.87, 124.49, 122.17, 120.63, 14.61, 13.16;
M.S.: m/z- 273, 274 (M+1), 275 (M+2), 241 (M–S), 195,
163; CHN calcd. for C13H11N3S2, 273.37, C, 57.12; H, 4.06;
N, 15.37. Found C, 56.99; H, 3.99; N, 15.09.
2.1.4. 6-Ethyl-2-(pyridin-2-yl)thieno[2,3-d]pyrimidine-4(3H)-
thione 4(H4)
IR (KBr) cm1: 3260 (amine N–H), 2895 (Ar C–H), 1028
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.46 (1H, s, thioam-
ide), 8.72–7.31 (5H, m, arom), 2.756–1.20 (5H, s, aliphatic);
13C NMR (DMSO-d6) d (ppm): 176.63, 159.68, 149.40,
148.45, 148.40, 141.16, 137.60, 132.74 124.90, 124.74, 121.27,
26.17, 14.64; M.S.: m/z- 273, 274 (M+1), 275 (M+2), 241
(M–S), 195, 163; CHN calcd. for C13H11N3S2, 273.37, C,
57.12; H, 4.06; N, 15.37. Found C, 57.01; H, 3.99; N, 15.02.
2.1.5. 6-Ethyl-2-(pyridin-3-yl)thieno[2,3-d]pyrimidine-4(3H)-
thione 4(H5)
IR (KBr) cm1: 3215 (amine N–H), 2901 (Ar C–H), 1058
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.66 (1H, s, thioam-
ide), 8.80–7.30 (5H, m, arom), 2.74–1.22 (5H, s, aliphatic); 13C
NMR (DMSO-d6) d (ppm): 176.63, 159.76, 151.32, 148.72,
148.45, 141.16, 135.33, 132.74, 132.72, 124.90, 124.88, 26.17,
14.64; M.S.: m/z- 273, 274 (M+1), 275 (M+2), 21 (M–S),
195, 163; CHN calcd. for C13H11N3S2, 273.37, C, 57.12; H,
4.06; N, 15.37. Found C, 56.98; H, 4.01; N, 14.97.
2.1.6. 6-Ethyl-2-(pyridin-4-yl)thieno[2,3-d]pyrimidine-4(3H)-
thione 4(H6)
IR (KBr) cm1: 3279 (amine N–H), 2982 (Ar C–H), 1066
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.76 (1H, s, thioam-
ide), 8.66–7.30 (5H, m, arom), 2.75–1.20 (5H, s, aliphatic); 13C
NMR (DMSO-d6) d (ppm): 176.63, 157.19, 150.21, 148.45,
141.16, 137.74, 132.74, 124.90, 122.17, 26.17, 14.64; M.S.:
m/z- 273, 274 (M+1), 275 (M+2), 241 (M–S), 195, 163;
CHN calcd. for C13H11N3S2, 273.37, C, 57.12; H, 4.06; N,
15.37. Found C, 56.93; H, 4.01; N, 15.11.
2.1.7. 2-(Pyridin-2-yl)-4b,5,6,7,8,8a-
hexahydro[1]benzothieno[2,3-d]pyrimidine-4(3H)-thione
4(H7)
IR (KBr) cm1: 3160 (amineN–H), 2870 (ArC–H), 1092 (C‚S);
1H NMR (DMSO-d6) d (ppm): 12.82 (1H, s, thioamide), 8.72–
7.46 (4H, m, arom.), 2.95–1.89 (8H, m, aliphatic); 13C NMR
(DMSO-d6) d (ppm): 173.73, 160.20, 149.40, 148.40, 148.26,
137.60, 133.08, 124.74, 121.27, 55.40, 50.36, 28.87, 26.27,
24.80, 24.05; M.S.: m/z- 301, 302 (M+1), 303 (M+2), 269 (M–
S), 223, 191; CHN calcd. for C15H15N3S2, 301.42, C, 59.77; H,
5.02; N, 13.94. Found C, 59.13; H, 4.99; N, 13.37.
2.1.8. 2-(Pyridin-3-yl)-4b,5,6,7,8,8a-
hexahydro[1]benzothieno[2,3-d]pyrimidine-4(3H)-thione
4(H8)
IR (KBr) cm1: 3153 (amine N–H), 2876 (Ar C–H), 1088
(C‚S); 1HNMR(DMSO-d6) d (ppm): 12.51 (1H, s, thioamide),
8.88–7.56 (4H, m, arom.), 2.87–1.88 (8H, m, aliphatic); 13C
NMR (DMSO-d6) d (ppm): 173.73, 158.74, 151.32, 148.72,
148.26, 135.33, 133.08, 132.71, 124.87, 55.40, 50.36, 28.87,26.27, 24.80, 24.05; M.S.: m/z- 301, 302 (M+1), 303 (M+2),
269 (M–S), 223, 191; CHN calcd. for C15H15N3S2, 301.42, C,
59.77; H, 5.02; N, 13.94 Found C, 59.11; H, 4.97; N, 13.45.
2.1.9. 2-(Pyridin-4-yl)-4b,5,6,7,8,8a-
hexahydro[1]benzothieno[2,3-d]pyrimidine-4(3H)-thione
4(H9)
IR (KBr) cm1: 3185 (amine N–H), 2883 (Ar C–H), 1022
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.87 (1H, s, thioam-
ide), 8.66–7.78 (4H, m, arom.), 2.87–1.87 (8H, m, aliphatic);
13C NMR (DMSO-d6) d (ppm): 173.73, 156.59, 150.21,
148.26, 137.74, 133.08, 122.17, 55.40, 50.36, 28.87, 26.27,
24.80, 24.05; M.S.: m/z- 301, 302 (M+1), 303 (M+2), 269
(M–S), 223, 191; CHN calcd. for C15H15N3S2, 301.42, C,
59.77; H, 5.02; N, 13.94. Found C, 59.71; H, 4.96; N, 13.59.
2.1.10. 5-(4-Chlorophenyl)-2-(pyridin-2-yl)thieno[2,3-d]pyrim
idine-4(3H)-thione 4(H10)
IR (KBr) cm1: 3252 (amine N–H), 2962 (Ar C–H), 1123
(C‚S), 798 (Cl); 1H NMR (DMSO-d6) d (ppm): 12.73 (1H,
s, thioamide); 8.72–7.43 (9H, m, arom.), 13C NMR (DMSO-
d6) d (ppm): 183.36, 159.21, 154.83, 149.40, 148.40, 140.03,
137.60, 133.95, 133.82, 132.76, 128.23, 126.16, 124.74, 121.27,
114.51; M.S.: m/z- 355, 356 (M+1), 357 (M+2), 323 (M–S),
277, 245; CHN calcd. for C17H10ClN3S2, 355.86, C, 57.38;
H, 2.83; N, 11.81. Found C, 57.23; H, 2.51; N, 11.67.
2.1.11. 5-(4-Chlorophenyl)-2-(pyridin-3-yl)thieno[2,3-d]pyrim
idine-4(3H)-thione 4(H11)
IR (KBr) cm1: 3228 (amine N–H), 2976 (Ar C–H), 1137
(C‚S), 789 (Cl); 1H NMR (DMSO-d6) d (ppm): 12.60 (1H,
s, thioamide), 8.92–7.43 (9H, m, arom.); 13C NMR (DMSO-
d6) d (ppm): 183.36, 159.32, 154.83, 151.32, 148.72, 140.03,
135.33, 133.95, 133.82, 132.76, 132.72, 128.23, 126.16, 124.87,
114.51; M.S: m/z- 355, 356 (M+1), 357 (M+2), 323 (M–S),
277, 245; CHN calcd. for C17H10ClN3S2, 355.86, C, 57.38;
H, 2.83; N, 11.81. Found C, 57.02; H, 2.66; N, 11.77.
2.1.12. 5-(4-Chlorophenyl)-2-(pyridin-4-yl)thieno[2,3-d]pyrim
idine-4(3H)-thione 4(H12)
IR (KBr) cm1: 3247 (amine N–H), 2953 (Ar C–H), 1101
(C‚S), 789 (Cl); 1H NMR (DMSO-d6) d (ppm): 12.80 (1H,
s, thioamide); 8.66–7.44 (9H, m, arom.), 13C NMR (DMSO-
d6) d (ppm): 183.36, 156.95, 154.83, 150.21, 140.03, 137.74,
133.95, 133.82, 132.76, 128.23, 126.16, 122.17, 114.51; M.S.:
m/z- 355, 356 (M+1), 357 (M+2), 323 (M–S), 277, 245;
CHN calcd. for C17H10ClN3S2, 355.86, C, 57.38; H, 2.83; N,
11.81. Found C, 57.11; H, 2.69; N, 11.73.
2.1.13. 6-Methyl-5-phenyl-2-(pyridin-2-yl)thieno[2,3-
d]pyrimidine-4(3H)-thione 4(H13)
IR (KBr) cm1: 3183 (amine N–H), 2912 (Ar C–H), 1198
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.57 (1H, s, thioam-
ide), 8.72–7.35 (9H, m, arom.), 2.27 (3H, m, aliphatic); 13C
NMR (DMSO-d6) d (ppm): 184.10, 159.30, 154.38, 149.40,
148.40, 141.75, 137.60, 134.09, 132.90, 128.33, 127.92, 127.55,
124.74, 121.27, 106.05, 18.35; M.S.: m/z- 335, 336 (M+1),
337 (M+2), 303 (M–S), 257, 225; CHN calcd. for
C18H13N3S2, 335.44, C, 64.45; H, 3.91; N, 12.53. Found C,
64.11; H, 3.88; N, 12.09.
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d]pyrimidine-4(3H)-thione 4(H14)
IR (KBr) cm1: 3193 (amine N–H), 2925 (Ar C–H), 1204
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.56 (1H, s, thioam-
ide), 8.92–7.29 (9H, m, arom.), 2.26 (3H, m, aliphatic); 13C
NMR (DMSO-d6) d (ppm): 184.35, 184.10., 159.13, 154.38,
151.32, 148.72, 141.75, 135.33, 134.09, 132.90, 132.71, 128.33,
127.92, 127.55, 124.87, 106.05; M.S.: m/z- 335, 336 (M+1),
337 (M+2), 303 (M–S), 257, 225; CHN calcd. for
C18H13N3S2, 335.44 C, 64.45; H, 3.91; N, 12.53. Found C,
64.43; H, 3.79; N, 12.22.
2.1.15. 6-Methyl-5-phenyl-2-(pyridin-4-yl)thieno[2,3-d]pyrim
idine-4(3H)-thione 4(H15)
IR (KBr) cm1: 3179 (amine N–H), 2905 (Ar C–H), 1183
(C‚S); 1HNMR(DMSO-d6) d (ppm): 12.79 (1H, s, thioamide),
8.66–7.29 (9H, m, arom.), 2.27 (3H, m, aliphatic); 13C NMR
(DMSO-d6) d (ppm): 184.10, 156.69, 154.38, 150.21, 141.75,
137.74, 134.09, 132.90, 128.33, 127.92 127.55, 122.17, 106.05,
18.35; M.S.: m/z- 335, 336 (M+1), 337 (M+2), 303 (M–S),
257, 225; CHN calcd. for C18H13N3S2, 335.44, C, 64.45; H,
3.91; N, 12.53. Found C, 64.37; H, 3.77; N, 12.19.
2.1.16. 2-(Methylsulfanyl)-5,6,7,8-tetrahydro[1]benzothieno[2,
3-d]pyrimidine-4(3H)-thione 4(H16)
IR (KBr) cm1: 3152 (amine N–H), 2920 (Ar C–H), 1103
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.71 (1H, s, thioam-
ide), 3.06–1.76 (8H, m, aliphatic); 2.59 (3H, m, aliphatic); 13C
NMR (DMSO-d6) d (ppm): 181.28, 156.92, 154.51, 128.12,
125.40, 115.38, 25.74, 25.17, 23.02, 22.08, 21.33; M.S.: m/z-
268, 269 (M+1), 270 (M+2), 236 (M–S), 222, 183; CHN
calcd. for C11H12N2S3, 268, C, 49.22; H, 4.51; N, 10.44. Found
C, 48.98; H, 4.61; N, 10.01.
2.1.17. 2-(Ethylsulfanyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]
pyrimidine-4(3H)-thione 4(H17)
IR (KBr) cm1: 3258 (amine N–H), 2910 (Ar C–H), 1130
(C‚S), 1H NMR (DMSO-d6) d (ppm): 12.76 (1H, s, thioam-
ide), 3.07–1.80 (8H, m, aliphatic); 2.59–1.75 (5H, m, aliphatic);
13C NMR (DMSO-d6) d (ppm): 181.28, 156.92, 154.51, 128.12,
125.40, 115.38, 25.74, 25.17, 23.02, 22.08, 21.33; M.S.: m/z-
282, 283, (M+1), 284 (M+2), 252 (M–S), 222, 183; CHN
calcd. for C12H14N2S3, 282, C, 51.03; H, 5.00; N, 9.92. Found
C, 50.95; H, 5.04; N, 9.71.
2.1.18. 2-sulfanyl-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrim
idine-4(3H)-thione 4(H18)
IR (KBr) cm1: 3281 (amineN–H), 2943 (Ar C–H), 2710 (S–H),
1103 (C‚S); 1H NMR (DMSO-d6) d (ppm): 12.89 (1H, s, thio-
amide), 3.06–1.76 (8H, m, aliphatic); 2.87 (1H, s, aliphatic); 13C
NMR (DMSO-d6) d (ppm): 180.52, 175.85, 155.89, 128.12,
125.40, 124.07, 25.74, 25.17, 23.02, 22.08; M.S.: m/z- 254, 255
(M+1), 256 (M+2), 224 (M–S), 222, 183; CHN calcd. for
C10H10N2S3, 254, C, 47.21; H, 3.96; N, 11.01. Found C, 47.01;
H, 3.57; N, 10.93.
2.1.19. 5,6-Dimethyl-2-(methylsulfanyl)thieno[2,3-d]pyrimidine-
4(3H)-thione 4(H19)
IR (KBr) cm1: 3281 (amine N–H), 2993 (Ar C–H), 1126
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.67 (1H, s, thioam-ide), 2.62 (3H, s, CH3), 2.49 (3H, s, CH3), 2.34 (3H, s, CH3);
13C NMR (DMSO-d6) d (ppm): 181.44, 154.51, 153.94,
125.87, 120.63, 116.47, 21.33, 14.61, 13.16; M.S.: m/z- 242,
243 (M+1), 244 (M+2), 212 (M–S), 196, 156; CHN calcd.
for C9H10N2S3, 242, C, 44.60; H, 4.16; N, 11.56. Found C,
44.23; H, 4.21; N, 11.10.
2.1.20. 2-(Ethylsulfanyl)-5,6-dimethylthieno[2,3-d]pyrimidine-
4(3H)-thione 4(H20)
IR (KBr) cm1: 3263 (amine N–H), 2978 (Ar C–H), 1683
(C‚C), 1112 (C‚S); 1H NMR (DMSO-d6) d (ppm): 12.79
(1H, s, thioamide), 2.65 (5H, s, CH3), 2.47 (3H, s, CH3),
2.31 (3H, s, CH3);
13C NMR (DMSO-d6) d (ppm): 181.44,
154.51, 153.94, 125.87, 120.63, 116.47, 21.33, 14.61, 13.16;
M.S.: m/z- 256, 257 (M+1), 258 (M+2), 226 (M-S), 196,
156; CHN calcd. for C10H12N2S3, 256, C, 46.84; H, 4.72; N,
10.93. Found C, 46.68; H, 4.78; N, 10.81.
2.1.21. 5,6-Dimethyl-2-sulfanylthieno[2,3-d]pyrimidine-4(3H)-
thione 4(H21)
IR (KBr) cm1: 3286 (amine N–H), 2997 (Ar C–H), 2768 (S–
H), 1137 (C‚S); 1H NMR (DMSO-d6) d (ppm): 12.55 (1H, s,
thioamide), 2.94 (1H, s, CH3), 2.49 (3H, s, CH3), 2.34 (3H, s,
CH3);
13C NMR (DMSO-d6) d (ppm): 180.10, 175.85, 155.28,
131.73, 125.87, 120.63, 14.61, 13.16; M.S.: m/z- 228, 229
(M+1), 230 (M+2), 198 (M–S), 196, 156; CHN calcd. for
C8H8N2S3, 228, C, 42.08; H, 3.53; N, 12.27. Found C, 41.98;
H, 3.49; N, 12.09.
2.1.22. 6-Methyl-2-(methylsulfanyl)-5-phenylthieno[2,3-d]pyrim
idine-4(3H)-thione 4(H22)
IR (KBr) cm1: 3288 (amine N–H), 2978 (Ar C–H), 1195
(C‚S); 1H NMR (DMSO-d6) d (ppm):12.85 (1H, s, thioam-
ide), 7.48–7.35 (5H, m, arom), 2.60 (3H, s, CH3), 2.45 (3H,
s, CH3);
13C NMR (DMSO-d6) d (ppm): 180.78, 154.51,
151.99, 141.75, 132.90, 128.33, 127.92, 127.55, 119.91,
106.05, 21.33, 18.35; M.S.: m/z- 304, 305 (M+1), 306
(M+2), 274 (M–S), 258, 219; CHN calcd. for C14H12N2S3,
304, C, 55.23; H, 3.97; N, 9.20. Found C, 55.12; H, 3.88;
N, 9.06.
2.1.23. 2-(Ethylsulfanyl)-6-methyl-5-phenylthieno[2,3-d]pyrim
idine-4(3H)-thione 4(H23)
IR (KBr) cm1: 3263 (amine N–H), 2955 (Ar C–H), 1189
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.64 (1H, s, thioam-
ide), 7.45–7.31 (5H, m, arom), 2.58 (5H, s, CH3), 2.43 (3H, s,
CH3);
13C NMR (DMSO-d6) d (ppm): 180.78, 154.51, 151.99,
141.75, 132.90, 128.33, 127.92, 127.55, 119.91, 106.05, 21.33,
18.35; M.S.: m/z- 318, 319 (M+1), 320 (M+2), 288 (M–S),
258, 219; CHN calcd. for C15H14N2S3, 318, C, 56.57; H,
4.43; N, 8.80. Found C, 56.46; H, 4.39; N, 8.67;
2.1.24. 6-Methyl-5-phenyl-2-sulfanylthieno[2,3-d]pyrimidine-
4(3H)-thione 4(H24)
IR (KBr) cm1: 3291 (amine N–H), 2982 (Ar C–H), 1191
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.53 (1H, s, thioam-
ide), 7.48–7.35 (5H, m, arom), 2.90 (1H, s, CH3), 2.45 (3H, s,
CH3);
13C NMR (DMSO-d6) d (ppm): 179.74, 175.85, 155.37,
141.75, 133.71, 132.90, 128.33, 127.92, 127.55, 106.05, 18.35;
M.S.: m/z- 290, 291 (M+1), 292 (M+2), 260 (M-S), 218,
S268 S.B. Bari, N.G. Haswani219; CHN calcd. for C13H10N2S3, 290, C, 53.76; H, 3.47; N,
9.65. Found C, 53.69; H, 3.49; N, 9.59.
2.1.25. 5-(4-Methoxyphenyl)-2-(methylsulfanyl)thieno[2,3-d]
pyrimidine-4(3H)-thione 4(H25)
IR (KBr) cm1: 3212 (amine N–H), 2879 (Ar C–H), 1187
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.72 (1H, s, thioam-
ide), 7.38–7.09 (4H, m, arom), 7.37 (1H, m, arom), 3.80 (3H, s,
CH3), 2.60 (1H, s, aliphatic); 13C NMR (DMSO-d6) d (ppm):
181.36, 154.57, 149.85, 140.03, 138.23, 133.82, 128.96, 128.74,
124.04, 114.51, 21.40, 21.33; M.S.: m/z- 320, 321 (M+1), 322
(M+2), 290 (M–S), 274, 235; CHN calcd. for C14H12N2OS3,
320, C, 52.47; H, 3.77; N, 8.74. FoundC, 53.69; H, 3.49; N, 9.59.
2.1.26. 2-(Ethylsulfanyl)-5-(4-methoxyphenyl)thieno[2,3-d]
pyrimidine-4(3H)-thione 4(H26)
IR (KBr) cm1: 3228 (amine N–H), 2887 (Ar C–H), 1176
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.66 (1H, s, thioam-
ide), 7.38–7.08 (4H, m, arom), 7.37 (1H, m, arom), 3.78 (3H, s,
aliphatic); 3.15–1.31 (5H, s, aliphatic); 13C NMR (DMSO-d6)
d (ppm): 181.36, 154.57, 149.85, 140.03, 138.23, 133.82, 128.96,
128.74, 124.04, 114.51, 21.40, 21.33; M.S.: m/z- 334, 335
(M+1), 336 (M+2), 304 (M–S), 274, 235; CHN calcd. for C15-
H14N2OS3, 334, C, 53.86; H, 4.22; N, 8.38. Found C, 53.79; H,
4.28; N, 8.24.
2.1.27. 2-(Propylsulfanyl)-5,6,7,8-tetrahydro[1]benzothieno[2,
3-d]pyrimidine-4(3H)-thione 4(H27)
IR (KBr) cm1: 3258 (amine N–H), 2918 (Ar C–H), 1115
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.89 (1H, s, thioam-
ide), 3.49–2.71 (8H, m, arom), 3.37 (2H, t, CH2), 1.78 (2H, m,
CH2), 1.62–0.98 (3H, t, CH3);
13C NMR (DMSO-d6) d (ppm):
180.34, 163.25, 155.84, 128.12, 125.40, 122.62, 34.21, 25.74,
25.17, 24.43, 23.02, 22.08, 12.50; M.S.: m/z-296, 297 (M+1),
298 (M+2), 266 (M–S), 222, 183; CHN calcd. for
C13H16N2S3, 296, C, 52.67; H, 5.44; N, 9.45. Found C,
52.56; H, 5.39; N, 9.36.
2.1.28. 5,6-Dimethyl-2-(propylsulfanyl)thieno[2,3-d]pyrimidine
-4(3H)-thione 4(H28)
IR (KBr) cm1: 3279 (amine N–H), 2986 (Ar C–H), 1138
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.71 (1H, s, thioam-
ide), 3.40 (2H, t, SCH2), 2.39 (3H, s, CH3), 2.34 (3H, s, CH3),
1.66 (2H, m, CH2), 1.62–0.97 (3H, t, CH3);
13C NMR (DMSO-
d6) d (ppm): 179.88, 163.25, 154.88, 129.99, 125.87, 120.63,
34.21, 24.43, 14.61, 13.16, 12.50; M.S.: m/z- 270, 271 (M+1),
272 (M+2), 240 (M–S), 196, 157; CHN calcd. for
C11H14N2S3, 270, C, 48.85 H, 5.22; N, 10.36. Found C,
48.68 H, 5.13; N, 10.34.
2.1.29. 6-Methyl-5-phenyl-2-(propylsulfanyl)thieno[2,3-d]pyrim
idine-4(3H)-thione 4(H29)
IR (KBr) cm1: 3293 (amine N–H), 2967 (Ar C–H), 1178
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.64 (1H, s, thi-
oamide), 7.48–7.31 (5H, m, arom.), 3.39 (2H, t, SCH2),
2.45 (3H, s, CH3), 1.64 (2H, m, CH2), 1.02 (3H, t,
CH3);
13C NMR (DMSO-d6) d (ppm): 179.47, 163.25,
155.29, 141.75, 133.09, 132.90, 128.33, 127.92, 127.55,
106.05, 34.21, 24.43, 18.35, 12.50; M.S.: m/z-332, 334
(M+1), 335 (M+2), 302 (M-S), 258, 219; CHN calcd.for C16H16N2S, 332, C, 57.79; H, 4.85; N, 8.42. Found
C, 57.63 H, 4.76; N, 8.39.
2.1.30. 5-(4-Methoxyphenyl)-2-(propylsulfanyl)thieno[2,3-d]
pyrimidine-4(3H)-thione 4(H30)
IR (KBr) cm1: 3236 (amine N–H), 2867 (Ar C–H), 1159
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.76 (1H, s, thioam-
ide), 7.38 (1H, s, arom.), 7.16–7.08 (4H, m, arom.), 3.39 (2H,
t, SCH2), 2.35 (3H, s, CH3), 1.66 (2H, m, CH2), 0.98 (3H, t,
CH3);
13C NMR (DMSO-d6) d (ppm): 180.55, 162.83, 152.10,
140.03, 138.23, 135.67, 133.82, 128.96, 128.74, 114.51, 34.21,
24.43, 21.40, 12.50; M.S.: m/z-348, 349 (M+1), 350 (M+2),
318 (M–S), 275, 235; CHN calcd. for C16H16N2OS3, 348, C,
55.14; H, 4.63; N, 8.04. Found C, 55.04 H, 4.67; N, 7.96.
2.1.31. 5-(4-Chlorophenyl)-2-(propylsulfanyl)thieno[2,3-d]pyrim
idine-4(3H)-thione 4(H31)
IR (KBr) cm1: 3249 (amine N–H), 2936 (Ar C–H), 2754 (S–
H), 1129 (C‚S); 1H NMR (DMSO-d6) d (ppm): 12.69 (1H, s,
thioamide), 7.39 (1H, s, arom.), 7.51–7.43 (4H, m, arom.), 3.39
(2H, t, SCH2), 1.67 (2H, m, CH2), 1.03 (3H, t, CH3);
13C NMR
(DMSO-d6) d (ppm): 180.55, 162.83, 152.10, 140.03, 135.67,
133.95, 133.82, 128.23, 126.16, 114.51, 34.21, 24.43, 12.50;
M.S.: m/z- 352, 353 (M+1), 354 (M+2), 322 (M–S), 278,
239;CHN calcd. for C15H13ClN2S3, 352, C, 51.05; H, 3.71;
N, 7.94. Found C, 51.05 H, 3.71; N, 7.94.
2.1.32. 2-(Butylsulfanyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-
d]pyrimidine- 4(3H)-thione 4(H32)
IR (KBr) cm1: 3196 (amine N–H), 2856 (Ar C–H), 1138
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.86 (1H, s, thioam-
ide), 3.39 (2H, t, CH2), 3.07–2.71 (8H, m, arom), 1.96 (2H, m,
CH2), 1.45 (2H, m, CH2) 0.92 (3H, t, CH3);
13C NMR (DMSO-
d6) d (ppm): 180.34, 163.25, 155.84, 128.12, 125.40, 122.62,
30.97, 30.77, 25.74, 25.17, 23.02, 22.08, 21.44, 13.58; M.S.:
m/z- 310, 311 (M+1), 312 (M+2), 280 (M–S), 222, 183;
CHN calcd. for C14H18N2S3, 310, C, 54.15; H, 5.84; N, 9.02.
Found C, 54.09; H, 5.87; N, 8.93.
2.1.33. 2-(Butylsulfanyl)-5,6-dimethylthieno[2,3-d]pyrimidine-
4(3H)-thione 4(H33)
IR (KBr) cm1: 3179 (amine N–H), 2876 (Ar C–H), 1096
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.68 (1H, s, thioam-
ide), 3.41 (2H, t, SCH2), 2.34 (3H, s, CH3), 2.31 (3H, s, CH3),
1.96 (2H, m, CH2), 1.46 (2H, m, CH2), 0.96 (3H, t, CH3);
13C
NMR (DMSO-d6) d (ppm): 179.88, 163.25, 154.88, 129.99,
125.87, 120.63, 30.97, 30.77, 21.44, 14.61, 13.58, 13.16; M.S.:
m/z- 284, 285 (M+1), 286 (M+2), 254 (M–S), 196, 157;
CHN calcd. for C12H16N2S3, 284, C, 50.67; H, 5.67; N, 9.85.
Found C, 50.56; H, 5.59; N, 9.73.
2.1.34. 2-(butylsulfanyl)-6-methyl-5-phenylthieno[2,3-d]pyrim
idine-4(3H)-thione 4(H34)
IR (KBr) cm1: 3196 (amine N–H), 2879 (Ar C–H), 1145
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.68 (1H, s, thioam-
ide), 7.48–7.35 (5H, m, arom.), 3.37 (2H, t, SCH2), 2.45 (3H, s,
CH3), 1.90 (2H, m, CH2), 1.45 (2H, m, CH2), 0.94 (3H, t,
CH3);
13C NMR (DMSO-d6) d (ppm): 179.47, 163.25,
155.29, 141.75, 133.09, 132.90, 128.33, 127.92, 127.55, 106.05,
30.97, 30.77, 21.44, 18.35, 13.58; M.S.: m/z- 346, 347 (M+1),
Design, synthesis and molecular docking study of thienopyrimidin-4(3H)-thiones S269348 (M+2), 216 (M–S), 258, 218; CHN calcd. for C17H18N2S3,
346, C, 58.92; H, 5.24; N, 8.08. Found C, 58.79; H, 5.27; N,
7.98.
2.1.35. 2-(Butylsulfanyl)-5-(4-methoxyphenyl)thieno[2,3-d]pyrim
idine-4(3H)-thione 4(H35)
IR (KBr) cm1: 3321 (amine N–H), 2815 (Ar C–H), 1087
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.76 (1H, s, thioam-
ide), 7.39 (1H, s, arom.), 7.16–7.08 (4H, m, arom.), 3.37 (2H, t,
SCH2), 2.33 (3H, s, CH3), 1.88 (2H, m, CH2), 1.44 (2H, m,
CH2), 0.92 (3H, t, CH3);
13C NMR (DMSO-d6) d (ppm):
180.55, 162.83, 152.10, 140.03, 138.23, 135.67, 133.82, 128.96,
128.74, 114.51, 30.97, 30.77, 21.44, 21.41, 13.58; M.S.: m/z-
362, 363 (M+1), 364 (M+2), 332 (M–S), 274, 234; CHN
calcd. for C17H18N2OS3, 362, C, 56.32; H, 5.00; N, 7.73.
Found C, 56.26; H, 4.98; N, 7.68.
2.1.36. 2-(Butylsulfanyl)-5-(4-chlorophenyl)thieno[2,3-d]pyrim
idine-4(3H)-thione 4(H36)
IR (KBr) cm1: 3187 (amine N–H), 2957 (Ar C–H), 1134
(C‚S); 1H NMR (DMSO-d6) d (ppm): 12.75 (1H, s, thioam-
ide), 7.51–7.39 (4H, m, arom.), 7.38 (1H, s, arom.), 3.37 (2H, t,
SCH2), 1.89 (2H, m, CH2), 1.45 (2H, m, CH2), 0.94 (3H, t,
CH3);
13C NMR (DMSO-d6) d (ppm): 180.55, 162.83,
152.10, 140.03, 135.67, 133.95, 133.82, 128.23, 126.16, 114.51,
30.97, 30.77, 21.44, 13.58; M.S.: m/z-365, 366 (M+1), 367
(M+2), 336 (M–S), 278, 238; CHN calcd. for C16H14ClN2S3,
365, C, 52.51; H, 3.86; N, 7.66; Found C, 52.48; H, 3.79; N,
7.58.
2.2. Biological activity
All synthesized compounds, 4(H1–H36), were screened for
activity against Aspergillus niger (NCIM 545), Penicillium
chrysogenum (NCIM 709), and C. albicans (NCIM 3471) in
DMSO using the disk diffusion method [24]. Potato dextrose
agar was prepared by dissolving peptone (0.05 g), yeast extract
(0.3 g), glucose (1.0 g), and malt extract (0.3 g) in distilled
water (100 mL) and adjusting the pH to 6.4. Normal saline
was used to make a suspension of fungal spores for lawning.
A loopful of a particular fungal strain was transferred to
3 mL of saline to get a suspension of the corresponding species.
Twenty milliliters of agar media was poured into an empty,
sterile petri dish. The excess suspension was decanted, and
the plates were maintained in an incubator at 37 C for 1 h
for drying. Agar disks were made using these seeded agar
plates, and 10 lg/mL of a test compound in DMSO was added
to each disk. A control was also prepared in the same way
using DMSO. All the antifungal assays were performed in trip-
licates and petri plates maintained at 37 C for 4 days. The
activity of each compound was compared with that of keto-
conazole, which was used as a standard.
The minimum inhibitory concentration (MIC) values were
determined for those fungi that were sensitive to the com-
pounds in the disk diffusion assay. The MIC is deﬁned as
the lowest concentration of a compound with which there
was no visible fungal growth after incubation. The broth dilu-
tion method was used to determine the MIC values. The pro-
cedure followed was as described in the literature [24]. The
compounds were prepared at the highest concentration(1 mg/mL), and serial twofold dilutions were made to obtain
concentrations ranging from 0.06 to 1054 lg/mL.
2.3. Docking study
The degree to which the synthesized molecules will affect their
target in terms of structural and chemical complementation
was explored using the Glide 4.5 [25] module of the Schro¨ding-
er molecular modeling interface. Glide searches for favorable
interactions between one or more ligand molecules and a
receptor molecule using a grid-based method.
For the present study, the X-ray crystal structure of the
twinned 1.85 A˚ ofC. albicans dihydrofolate reductase (PDB en-
try: 1AI9) was taken from PDB (www.rscb.org). Before dock-
ing, the proteins were prepared using the protein preparation
wizard (Maestro 8.0, Schro¨dinger LLC, 2007 [26]), removing
the water molecule and cofactors from the proteins, optimizing
hydrogen bonding and deleting the ligand present in the crystal
structure. The solvent molecules were deleted, and the bond or-
der of the crystal ligand and protein was adjusted. The struc-
tures were minimized up to 0.30 A˚ RMSD. The ligands were
built using the build panel of Maestro 8.0 (LigPrep 2.1 [28],
Schro¨dinger LLC, 2007 [27]) and prepared using LigPrep2.1
and the OPLS-2005 force ﬁeld [29]. Using the extra precision
(XP) mode of Glide 4.5, all the molecules were docked into
the active site of a target molecule, and ﬁnal scoring was carried
out in terms of the Glide multi-ligand scoring function.
2.4. Drug likeness (Lipinski’s rule of ﬁve)
As a part of our study, the compliance of compounds to Lipin-
ski’s rule of ﬁve was evaluated. As discussed by Lipinski,
molecular properties are closely related to the oral bioavail-
ability of a drug. Although the cytotoxic effects of lead com-
pounds are thought to be primarily due to their ability to
modulate cell death, other factors such as solubility, stability
and/or efﬂux properties within the cell may also contribute.
The QikProp 3.2 was used to analyze drug likeness (Lipinski’s
rule of ﬁve).
3. Results and discussion
All synthesized compounds were characterized, and their spec-
tral data was obtained. The purity and homogeneity of the
compounds were conﬁrmed using single spot TLC. Spectral
analysis (IR, 1H NMR, 13C NMR and mass spectrometry)
of the compounds conﬁrmed the structures of the synthesized
compounds. The IR spectrum of H3 contains broadened N–H
bands, indicating the presence of amide fragments, in the area
vicinity of 3190 cm1. Strong C‚C bands are found at
1698 cm1, a strong C‚N band is observed at 1611 cm1,
and the characteristic C‚S and C–N stretching are seen in
the area of 1095 to 1210 cm1. In the 1H NMR spectra of com-
pound H3, the protons of the thioamide group were observed
as broad singlet at 12.58 ppm, and the remaining four aro-
matic protons showed mutilates at 8.66–7.70 ppm. The 13C
NMR spectra show chemical shift at 172.17–183.90 ppm,
which is due to the presence of oleﬁn linkage. The mass spec-
tral data of all the synthesized compounds are in accordance
with their estimated molecular weights.
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The synthetic route of the title compound 4 (H1–H36) is out-
lined in Scheme 1.
The 4,5 disubstituted 2-amino-3-carbethoxythiophenes
were synthesized by the well-known Gewald synthesis [17–
23]. The intermediate compounds 3 (H1–H36) were synthe-
sized by dry HCl gas catalyzed one spot condensation of the
appropriate 4,5 disubstituted 2-amino-3-carbethoxythiophenes
1 and with excellent yields, according to the procedure
reported in [16]. The title compounds 4 (H1–H36) were synthe-
sized by thionation of thienopyrimidin-4(3H)-ones 3 (H1–H36)
using Lawesson’s reagent. Physical data of the synthesized
compounds are shown in Table 1.
3.2. Antifungal activity
The antifungal activity of the novel 2-pyridyl-, 2-mercapto-
and 2-alkythiocyanates thieno[2,3-d] pyrimidin-4(3H)thiones2 51
2
1
2
Scheme 1 Synthetic pathway for t
Table 1 Physical data of the title compounds 4(H1–H36).
.
Compound
code
Molecular
formula
Mol. Wt. Melting
point (C)
Yield (%) Reaction
time (h)
C
co
4(H1) C13H11N3S2 273 188–191 88 11 4(
4(H2) C13H11N3S2 273 299–302 98 11 4(
4(H3) C13H11N3S2 273 342–345 79 11 4(
4(H4) C13H11N3S2 273 148–151 76 13 4(
4(H5) C13H11N3S2 273 223–226 85 13 4(
4(H6) C13H11N3S2 273 226–229 78 13 4(
4(H7) C15H15N3S2 301 196–200 91 11 4(
4(H8) C15H15N3S2 301 302–305 97 11 4(
4(H9) C15H15N3S2 301 311–314 92 11 4(
4(H10) C17H10ClN3S2 355 303–306 91 12 4(
4(H11) C17H10ClN3S2 355 302–305 95 12 4(
4(H12) C17H10ClN3S2 355 302–305 93 12 4(
4(H13) C18H13N3S2 335 164–167 84 12 4(
4(H14) C18H13N3S2 335 282–285 98 15 4(
4(H15) C18H13N3S2 335 248–251 87 15 4(
4(H16) C11H12N2S3 268 203–206 85 15 4(
4(H17) C12H14N2S3 282 212–215 78 12 4(
4(H18) C10H10N2S3 254 203–206 91 12 4(against fungal strains (C. albicans, A. niger and P. chrysoge-
num) is summarized in Table 2. Compounds 4(H11), 4(H18),
4(H32) show much better inhibition of growth compared with
that of ketoconazole.
3.3. Structure–activity relationship (SAR) and docking study
The synthesized compounds showed antifungal activity against
the fungal strains tested. The results reveal that the substituted
thienopyrimidine was responsible for the antifungal activity,
which was comparable with that of the standard, ketoconazole.
Indeed, compound H4 in which there is 2-sulfanyl and 5,6,7,8-
tetrahydrobenzo substitution on the thienopyrimidine ring, has
showed better antifungal activity compared with the standard.
Compounds having 2-pyridyl substitutions exhibited better
antifungal activity compared to 3-pyridyl-, 4-pyridyl-, 2-mer-
capto-, 2-mercaptomethyl, and 2-mercaptoethyl substitutions.
Mercaptobutyl substitution at position 2 also showed good
antifungal activity. Compounds having the tetrahydrobenzothi-1
2
he title compounds 4(H1–H36).
ompound
de
Molecular
formula
Mol. Wt. Melting
point (C)
Yield (%) Reaction
time (h)
H19) C9H10N2S3 242 195–198 81 12
H20) C10H12N2S3 256 211–214 79 13
H21) C8H8N2S3 228 205–208 85 13
H22) C14H12N2S3 304 268–271 74 13
H23) C15H14N2S3 318 255–258 79 14
H24) C13H10N2S3 290 278–281 85 14
H25) C14H12N2OS3 320 188–191 78 14
H26) C15H14N2OS3 334 179–182 89 11
H27) C13H16N2S3 296 121–224 62 11
H28) C11H14N2S3 270 189–172 58 11
H29) C16H16N2S 332 212–215 65 12
H30) C16H16N2OS3 348 208–211 57 12
H31) C15H13ClN2S3 352 214–217 69 12
H32) C14H18N2S3 310 243–246 63 14
H33) C12H16N2S3 284 246–249 55 14
H34) C17H18N2S3 346 237–240 62 14
H35) C17H18N2OS3 362 261–264 57 12
H36) C16H14ClN2S3 365 223–226 61 12
Table 2 Antifungal screening of the title compounds 4 (H1–H36), minimum inhibitory concentration (MIC) lg/mL.
Compound
code
Candida
albicans
Aspergillus niger Penicillium chrysogenum Compound code Candida albicans Aspergillus niger Penicillium chrysogenum
4(H1) 4 4 4 4(H19) 4 4 2
4(H2) 8 4 4 4(H20) 8 4 8
4(H3) 16 4 8 4(H21) 8 4 2
4(H4) 4 2 4 4(H22) 32 8 16
4(H5) 32 32 16 4(H23) 4 4 2
4(H6) 8 8 4 4(H24) 4 4 2
4(H7) 8 8 8 4(H25) 8 8 4
4(H8) 16 16 8 4(H26) 8 16 8
4(H9) 8 8 8 4(H27) 8 8 8
4(H10) 8 8 4 4(H28) 16 32 8
4(H11) 4 2 2 4(H29) 32 8 4
4(H12) 8 8 8 4(H30) 8 4 4
4(H13) 6 4 4 4(H31) 8 8 4
4(H14) 8 4 2 4(H32) 4 2 2
4(H15) 8 4 4 4(H33) 8 4 4
4(H16) 4 4 16 4(H34) 8 8 8
4(H17) 8 2 2 4(H35) 8 4 8
4(H18) 4 2 2 4(H36) 8 4 4
Ketoconazol 0.25 0.25 0.25 Ketoconazol 0.25 0.25 0.25
Table 3 Docking results of the title compounds 4(H1–H36).
Compound code Glide gscore Glide lipophilic Glide energy Compound code Glide gscore Glide lipophilic Glide energy
4(H18) 6.57 1.64 42.82 4(H30) 5.57 2.06 42.64
4(H4) 6.11 1.63 35.79 4(H12) 5.57 2.20 41.45
4(H1) 5.99 2.09 39.73 4(H6) 5.56 2.17 41.78
4(H11) 5.96 2.36 37.47 4(H35) 5.54 2.19 43.78
4(H17) 5.92 2.18 33.30 4(H25) 5.50 2.31 30.04
4(H23) 5.80 2.32 37.48 4(H15) 5.46 1.77 33.83
4(H24) 5.78 1.93 35.16 4(H7) 5.44 2.11 32.04
4(H13) 5.77 2.10 41.25 4(H33) 5.41 2.28 34.53
4(H32) 5.72 2.18 42.78 4(H14) 5.39 1.74 37.90
4(H26) 5.72 2.00 33.06 4(H8) 5.37 2.00 33.33
4(H9) 5.71 2.34 36.84 4(H2) 5.36 1.70 34.08
4(H36) 5.70 2.34 44.30 4(H20) 5.29 1.34 29.68
4(H16) 5.69 1.62 29.83 4(H28) 5.24 1.89 33.03
4(H21) 5.65 0.97 28.11 4(H3) 5.17 1.84 38.01
4(H10) 5.65 2.19 42.19 4(H29) 5.13 2.40 35.23
4(H27) 5.65 2.40 34.60 4(H5) 5.11 1.93 36.79
4(H19) 5.62 1.27 28.88 4(H22) 4.84 1.53 34.44
4(H31) 5.58 2.54 35.95 4(H34) 4.78 1.62 36.95
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Figure 1 Binding mode of 4(H18), 4(H1), 4(H4), and inactive compound 4(H15) in the X-ray crystal structure of DHFR (PDB code:
1AE9). Compound 4(H18) shows hydrogen bond interaction with THR58; Compound 4(H1) and Compound 4(H15) with ALA115
respectively; on the other hand compound 4(H15) is not showing any kind of hydrogen bonding interaction; may be the reason for its least
activity.
Table 4 Lipinski’s parameter data for the title compounds 4 (H1–H36).
.
Compound
code
Molecular
weight
Hydrogen
bond donor
Hydrogen
bond accepter
Q P log
Po/w
Rule
of ﬁve
Compound
code
Molecular Weight Hydrogen
bond donor
Hydrogen
bond accepter
Q P log
Po/w
Rule
of ﬁve
4(H1) 273 1 4 3.198 0 4(H19) 242 1 3 3.067 0
4(H2) 273 1 4.5 2.951 0 4(H20) 256 1 3 3.418 0
4(H3) 273 1 4.5 2.949 0 4(H21) 228 1.8 3 2.536 0
4(H4) 273 1 4 3.321 0 4(H22) 304 1 3 4.327 0
4(H5) 273 1 4.5 3.077 0 4(H23) 318 1 3 4.683 0
4(H6) 273 1 4.5 3.074 0 4(H24) 290 1.8 3 3.77 0
4(H7) 301 1 4 3.614 0 4(H25) 320 1 3.75 4.435 0
4(H8) 301 1 4.5 3.361 0 4(H26) 334 1 3.75 4.789 0
4(H9) 301 1 4.5 3.362 0 4(H27) 296 1 3 4.219 0
4(H10) 355 1 4 4.714 0 4(H28) 270 1 3 5.055 0
4(H11) 355 1 4.5 4.46 0 4(H29) 332 1 3 5.067 1
4(H12) 355 1 4.5 4.457 0 4(H30) 348 1 3.75 5.172 1
4(H13) 335 1 4 4.221 0 4(H31) 352 1 3 5.326 1
4(H14) 335 1 4.5 3.969 0 4(H32) 310 1 3 4.602 0
4(H15) 335 1 4.5 3.966 0 4(H33) 284 1 3 4.172 0
4(H16) 268 1 3 3.484 0 4(H34) 346 1 3 5.452 1
4(H17) 282 1 3 3.838 0 4(H35) 362 1 3.75 5.318 1
4(H18) 254 1.8 3 2.942 0 4(H36) 365 1 3 5.711 1
S272 S.B. Bari, N.G. Haswani
Design, synthesis and molecular docking study of thienopyrimidin-4(3H)-thiones S273ophene nucleus were found to be less active as compared to
other substituted thienopyrimidine compounds. However com-
pounds with dimethyl, chlorophenyl, or phenyl substitutions on
the thiophene residue also displayed good antifungal activity.
3.4. Docking study
All the synthesized compounds were subjected to grid-based
molecular docking studies. The results show that compounds
4(H18), 4(H4), 4(H1), 4(H11) and 4(H17) have good afﬁnity
to the active site residue (Table 3).
Binding mode of 4(H18), 4(H1), 4(H4), and inactive com-
pound 4(H15) in the X-ray crystal structure of DHFR (PDB
code: 1AE9) is shown in Fig. 1. Compound 4(H18) shows
hydrogen bond interaction with THR58; compounds 4(H1)
and 4(H15) with ALA115, respectively; on the other hand com-
pound 4(H15) is not showing any kind of hydrogen bonding
interaction, may be the probable reason for its lowest activity.
3.5. Drug likeness (Lipinski’s rule of ﬁve)
The QikProp 3.2 was used to analyze drug likeness (Lipinski’s
rule of ﬁve); the results are given in Table 4. It was found that
all the synthesized compounds comply with these rules with
the exception of 4(H29), 4(H30), 4(H31), 4(H34), 4(H35) and
4(H36). All Lipinski’s parameters are within the acceptable
range, thereby indicating their potential as a drug-like molecule.
4. Conclusion
A total of 36 compounds were synthesized and screened for
antifungal activity against C. albicans, A. niger, and P. chrysog-
enum. Among the compounds tested, 4(H1), 4(H4), 4(H11),
4(H13), 4(H17), 4(H18), 4(H23) and 4(H32) possess signiﬁcant
antifungal activities, while all the other thieno pyrimidines-
4(3H)-thione derivatives showed moderate antifungal activity
compared with the standard. In addition, the binding mode
of the tested compounds in the active site of C. albicans dihy-
drofolate reductase was predicted using a docking technique.
Results revealed that the orientation of the synthesized deriva-
tives in the C. albicans dihydrofolate reductase active site was
similar to that ofC. albicans dihydrofolate reductase inhibitors.
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